Celon Pharma SA (CLN) — Capital Reinvestment Ratio
Latest as of June 2025:
6.28x
Celon Pharma SA (CLN) has a Capital Reinvestment Ratio of 6.28x as of June 2025, meaning it reinvests 6% of its operating cash flow (zł3.51 Million) in capital expenditures (zł22.07 Million). See CLN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
6.28x
Capex / Operating Cash Flow
Operating Cash Flow
zł3.51 Million
PLN
Capital Expenditures
zł22.07 Million
PLN
Data as of
Jun 2025
Most recent filing
Celon Pharma SA Capital Reinvestment Ratio (2012–2021)
This chart tracks Celon Pharma SA's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for Celon Pharma SA (2012–2021)
Year-by-year Capital Reinvestment Ratio for Celon Pharma SA from 2012 to 2021. For live market cap and broader valuation context, see Celon Pharma SA (CLN) total market value.
| Year | Reinvestment Ratio | Operating CF (PLN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.94x | zł43.95 Million | zł41.35 Million | ▼ -32.7% |
| 2020 | 1.40x | zł70.90 Million | zł99.16 Million | ▼ -41.5% |
| 2018 | 2.39x | zł28.24 Million | zł67.46 Million | ▲ +92.9% |
| 2017 | 1.24x | zł25.30 Million | zł31.34 Million | ▲ +20.1% |
| 2016 | 1.03x | zł20.65 Million | zł21.29 Million | ▲ +20.4% |
| 2015 | 0.86x | zł52.37 Million | zł44.86 Million | ▼ -7.5% |
| 2014 | 0.93x | zł24.36 Million | zł22.55 Million | ▲ +38.6% |
| 2013 | 0.67x | zł8.45 Million | zł5.64 Million | ▲ +97.8% |
| 2012 | 0.34x | zł12.87 Million | zł4.34 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow